Please sign in to follow a disease.
Lymphoid neoplasm
MONDO:0005157A neoplasm composed of a lymphocytic cell population which is usually malignant (clonal) by molecular genetic and/or immunophenotypic analysis. Lymphocytic neoplasms include Hodgkin and non-Hodgkin lymphomas, acute and chronic lymphocytic leukemias, and plasma cell neoplasms.
Also known as: lymphocytic and plasma cell neoplasm, lymphocytic and plasma cell tumor, lymphocytic and plasma cell tumour, lymphocytic and plasmacytic neoplasm, lymphocytic neoplasm, lymphocytic tumor, lymphocytic tumour, lymphoid and plasma cell tumor
5948 clinical trials for this condition and its sub-types, 11 tagged with Lymphoid neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoid neoplasm
-
Lymphoma 606 trials · 4,243 incl. sub-types
27 sub-types
- B-cell neoplasm 304 trials · 3,167 incl. sub-types Sub-types →
- Non-Hodgkin lymphoma 526 trials · 2,897 incl. sub-types Sub-types →
- Primary organ-specific lymphoma 0 trials · 329 incl. sub-types Sub-types →
- Hodgkins lymphoma 262 trials · 326 incl. sub-types Sub-types →
- Mediastinal malignant lymphoma 6 trials · 180 incl. sub-types Sub-types →
- Pediatric lymphoma 3 trials · 141 incl. sub-types Sub-types →
- Peripheral T-cell lymphoma, not otherwise specified 61 trials
- Extranodal nasal NK/T cell lymphoma 51 trials
- Adult lymphoma 1 trial · 33 incl. sub-types Sub-types →
- Eye lymphoma 0 trials · 16 incl. sub-types Sub-types →
- B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma 11 trials · 12 incl. sub-types Sub-types →
- Gastrointestinal lymphoma 0 trials · 7 incl. sub-types Sub-types →
- Composite lymphoma 5 trials
- AIDS-related primary central nervous system lymphoma 3 trials
- Breast lymphoma 0 trials · 1 incl. sub-types Sub-types →
- Heart lymphoma 1 trial
- Bladder lymphoma 0 trials
- Chest wall lymphoma 0 trials Sub-types →
- Lung lymphoma 0 trials Sub-types →
- Methotrexate-associated lymphoproliferative disorders 0 trials
- Nasal cavity lymphoma 0 trials
- Ovarian lymphoma 0 trials
- Progressive transformation of germinal centers 0 trials
- Prostate lymphoma 0 trials
- Retroperitoneal lymphoma 0 trials
- Tracheal lymphoma 0 trials
- Ureteral lymphoma 0 trials
-
Lymphoid leukemia 23 trials · 1,360 incl. sub-types
3 sub-types
- Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- T-cell large granular lymphocyte leukemia 18 trials
-
Precursor lymphoblastic lymphoma/leukemia 12 trials · 1,342 incl. sub-types
4 sub-types
- Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types Sub-types →
- Lymphoblastic lymphoma 78 trials · 104 incl. sub-types Sub-types →
- T lymphoblastic leukemia/lymphoma 18 trials · 100 incl. sub-types Sub-types →
- B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality 0 trials · 59 incl. sub-types Sub-types →
-
Neoplasm of immature B and T cells 0 trials · 1,317 incl. sub-types
1 sub-type
- Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types Sub-types →
-
T-cell and NK-cell neoplasm 8 trials · 324 incl. sub-types
2 sub-types
- Neoplasm of mature T-cells or NK-cells 4 trials · 248 incl. sub-types Sub-types →
- T lymphoblastic leukemia/lymphoma 18 trials · 100 incl. sub-types Sub-types →
-
Malignant lymphatic vessel tumor 0 trials
Most studied deeper sub-types
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC